Agilon Health, Inc. (NYSE:AGL) Given Consensus Rating of “Hold” by Analysts

Agilon Health, Inc. (NYSE:AGL) has been given an average recommendation of “Hold” by the seventeen analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $2.7083.

A number of brokerages have commented on AGL. Royal Bank Of Canada upgraded shares of Agilon Health from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, December 3rd. Wells Fargo & Company decreased their price target on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. BTIG Research reiterated a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Barclays reduced their price objective on Agilon Health from $1.50 to $1.00 and set an “underweight” rating on the stock in a report on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st.

Key Stories Impacting Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Neutral Sentiment: Market context: AGL has seen increased trading activity and a short‑term price uptick despite the legal filings; that bounce may reflect low float, speculative trading or short covering rather than a change in fundamentals.
• Negative Sentiment: Rosen Law Firm reminds purchasers of AGL of the March 2, 2026 lead‑plaintiff deadline and is soliciting investors who suffered losses during the alleged class period — this is part of a coordinated push to identify lead plaintiffs and pursue a securities suit. Rosen Law Firm Notice
• Negative Sentiment: Multiple national firms (Pomerantz, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Levi & Korsinsky, The Gross Law Firm, Bernstein Liebhard, Kirby McInerney, Schall, etc.) have filed or issued investor notices seeking plaintiffs and claiming investor harm — the accumulation of these actions raises potential litigation, defense costs, and settlement risk for AGL. Representative PR Newswire Notice
• Negative Sentiment: Practical impact for investors: if a lead plaintiff is appointed and the litigation proceeds, AGL could face material legal liabilities, increased governance scrutiny, and downward pressure on the share price; monitor SEC filings, company disclosures, and any governmental inquiries closely. Bronstein Notice

Agilon Health Trading Up 8.3%

NYSE AGL opened at $0.44 on Monday. The stock has a market cap of $181.71 million, a PE ratio of -0.58 and a beta of 0.06. Agilon Health has a 12 month low of $0.34 and a 12 month high of $6.08. The company’s 50-day moving average price is $0.73 and its 200-day moving average price is $0.87.

Institutional Trading of Agilon Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC grew its holdings in Agilon Health by 243.3% during the 1st quarter. AQR Capital Management LLC now owns 501,440 shares of the company’s stock worth $2,171,000 after acquiring an additional 355,365 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Agilon Health by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 214,200 shares of the company’s stock worth $927,000 after purchasing an additional 7,209 shares during the period. Dynamic Technology Lab Private Ltd boosted its stake in shares of Agilon Health by 28.4% during the first quarter. Dynamic Technology Lab Private Ltd now owns 47,111 shares of the company’s stock valued at $204,000 after purchasing an additional 10,424 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Agilon Health by 6.6% during the first quarter. Goldman Sachs Group Inc. now owns 5,060,333 shares of the company’s stock valued at $21,911,000 after buying an additional 311,158 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Agilon Health during the second quarter valued at approximately $68,000.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.